Endocrinology - 3: Preventing complications of diabetes
Endocrinology - 3: Preventing complications of diabetes
复制标题
DOI：
10.5694/j.1326-5377.2003.tb05655.x
复制
发表时间：
2003-11-03
影响因子：
11.4
通讯作者：
Jerums, G
中科院分区：
文献类型：
--
作者：
Bate, KL;Jerums, G
糖尿病并发症很常见，几乎是糖尿病年管理费用的三倍。微血管并发症是1型糖尿病的主要风险，而大血管并发症是2型糖尿病发病率和死亡率的主要原因。控制高血糖(目标HbA(1c)水平小于或等于7%)和高血压(目标血压小于或等于130/80毫米汞柱)可预防这两种类型糖尿病的微血管并发症；一种多因素的方法，包括针对所有风险因素的行为改变和药物治疗，减少了2型糖尿病微血管和大血管并发症的发展。治疗血脂异常的好处在糖尿病人群中至少与非糖尿病人群一样大。血管紧张素转换酶抑制剂和小剂量阿司匹林适用于糖尿病和其他心血管风险因素的患者。定期的糖尿病并发症年度筛查可以确定可治疗的疾病。
Diabetes complications are common and almost triple the annual cost of managing diabetes.Microvascular complications are the major risk in type 1 diabetes, while macrovascular complications are the major cause of morbidity and mortality in type 2 diabetes.Control of hyperglycaemia (target HbA(1c) level less than or equal to 7%) and hypertension (target blood pressure less than or equal to 130/80 mmHg) prevents microvascular complications in both types of diabetes; a multifactorial approach, comprising behaviour modification and pharmacological therapy for all risk factors, reduces the development of micro- and macrovascular complications in type 2 diabetes.The benefit of treating dyslipidaemia is at least as great in the diabetic population as in the non-diabetic population.Angiotensin-converting enzyme inhibitors and low-dose aspirin are indicated in people with diabetes and other cardiovascular risk factors.Regular annual screening for diabetes complications allows treatable disease to be identified.